CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
letrozoledrug
Likely dose
letrozole 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00291135
NCT00291135Phase 2Completed
CompareCT.gov

Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy

Carol Fabian, MD·interventional·Posted Feb 13, 2006·Updated Jun 15, 2016

In Brief

A Phase 2 clinical trial evaluating letrozole for Breast Cancer. Completed, enrolled 42 participants across 1 site.

Detailed Summary

A pilot study to assess the effects of six months of letrozole on breast tissue risk markers in postmenopausal women on hormone replacement therapy at high risk of developing breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2006
Enrollment StartJan 1, 2003
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 20.4 years ago

Interventions

letrozoledrug

Letrozole 2.5 mg daily